NCT03773796View on ClinicalTrials.gov

Nabilone for Non-motor Symptoms in Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 6, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Parkinson Disease
Interventions
DRUG

Nabilone 0.25 mg

capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis

Trial Locations (1)

6020

Department of Neurology - Medical University Innsbruck, Innsbruck

All Listed Sponsors
lead

Medical University Innsbruck

OTHER

NCT03773796 - Nabilone for Non-motor Symptoms in Parkinson's Disease | Biotech Hunter | Biotech Hunter